insidemoney Posted - 08/27/24

$CELC Celcuity Inc. 14-Day RSI: 52.4 % from 52-Week Low: +108.0% % from 52-Week High: -21.4% Open Interest: 2,271 % Change: 0% Put/Call Ratio: 1.1 % Change: -0.1%

FlynancialAnalyst Posted - 1 month ago

$CELC $554M mc $XBI #ShortSqueeze name seeing accumulation above rising 10/40/80 wk SMAs FOUNDER LED, 16.69% insider owned Short float % rapidly cooling off from 20.6% 6 mths ago to just 9.3% today Pct of all funds long shares at record highs & rising TrendEdge.app/asset/CELC

intratio Posted - 1 month ago

$CELC Our mathematical model lets us believe that the stock price of this company clearly has a bad short-term setup and has really poor long-term fundamentals

OpenOutcrier Posted - 1 month ago

$CELC (-4.6% pre) Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update https://ooc.bz/l/40301

Stock_Titan Posted - 1 month ago

$CELC Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update https://www.stocktitan.net/news/CELC/celcuity-inc-reports-second-quarter-financial-results-and-provides-346wja0vw2al.html

intratio Posted - 1 month ago

https://www.intratio.com/stock-forecast/CELC Our network foresees the value of this company will fall sharply in the short-term and will have a very negative trend in the upcoming months $CELC

DonCorleone77 Posted - 1 month ago

$CELC From 5/16 - Celcuity assumed with a Buy at Craig-Hallum Craig-Hallum assumed coverage of Celcuity with a Buy rating with a price target of $27, up from $25. The firm notes Celcuity provided an update on the company's ongoing clinical trials on the Q1 call, with nothing groundbreaking. With funding through the first half of 2026, investors get to read through directly to three transformational data readouts. Craig-Hallum focuses solely on breast at the moment and thinks peak sales can be well over $2B from Geda in the 2L HR+/HER2-advanced breast setting alone. Also 5/16 From Stifel - Celcuity Inc. (CELC, $17.23, Buy; Target $40.00) - 1Q24 Recap: VIKTORIA-1 Milestones Are On-Track and Mgmt Voiced Confidence In Ph.3 Design Elements To Support Data Translation - Bradley Canino - The 1Q24 call reiterated 2H24 and 1H25 TLR milestones from the PIK3CA wild-type and PIK3CAm cohorts, respectively, of the 2L HR+ mBC VIKTORIA-1 trial. Remarks included continued emphasis on the importance of multi-nodal PI3K/AKT/mTOR plus CDK+ET inhibition to prolong durability beyond standard of care monotherapy/doublets. It also offered positive reinforcement for ph.3 translation of the supportive ph.1b data (~12m PFS), including the ph.3's exclusion of prior chemotherapy and inclusion of bone-only metastases patients (~20% estimated, vs. 0% in ph.1b). Management pointed to the alpelisib BYLieve cohorts that suggested high chemo exposure can create a ~30% PFS delta, and bone-only patients in palbo's PALOMA-2 analysis had a 50% greater PFS compared to those without. Management also offered forward commercial comments, likely in response to recent investor questioning, to outline that oncologists would prioritize efficacy (i.e., gedatolisib) even if IV, and ADCs would sit after endocrine therapies and before chemo. Reiterate BUY. From 5/30 - Celcuity announces plans to initiate Phase 3 trial of gedatolisib Celcuity announced that it plans to initiate a Phase 3 clinical trial to evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy resistant. In conjunction with its plan to conduct this study, Celcuity today entered into an amendment to an existing debt facility agreement and received an additional term loan of approximately $62 million. "There is an urgent need for better first-line treatment options for HR+/HER2- advanced breast cancer patients whose disease progressed while on or within 12 months of completing adjuvant endocrine for early breast cancer," said Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity. "We are very encouraged by the preliminary clinical data for gedatolisib as first-line treatment in patients with advanced breast cancer. In our Phase 1b trial that evaluated gedatolisib in combination with palbociclib and letrozole, median progression free survival was 48.6 months, and the ORR was 79%. These results highlighted the potential benefit of inhibiting the PI3K/AKT/mTOR pathway in treatment naive patients." Also From 5/30 - Celcuity prices 3.87M shares at $15.50 in underwritten common stock offering Celcuity announced the pricing of an underwritten offering of 3,871,000 shares of its common stock at an offering price of $15.50 per share. All of the securities are to be sold by Celcuity. Investors who have agreed to purchase shares in the offering include BVF Partners, Vivo Capital, Eventide Asset Management, Samlyn Capital, Driehaus Capital Management and Blue Owl Healthcare Opportunities. The offering is expected to close on or about May 31, 2024, subject to satisfaction of customary closing conditions. Gross proceeds to Celcuity from the offering are expected to be $60M, before deducting underwriting discounts and commissions and offering expenses. Celcuity intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, clinical trial expenditures, expansion of business development activities and other general corporate purposes. Clinical trial expenditures may include a Phase 3 clinical trial that Celcuity plans to initiate to evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer. Celcuity expects that its existing cash, cash equivalents and short-term investments and available borrowings under its recently announced amended and restated loan and security agreement, together with the net proceeds from this offering, will be sufficient to fund Celcuity's operating expenses and capital expenditure requirements through at least the second half of 2026. Leerink Partners, TD Cowen and Stifel acted as joint bookrunning managers for the offering. From 7/22 - Celcuity initiated with an Outperform at Leerink Leerink initiated coverage of Celcuity with an Outperform rating and $29 price target. Celcuity is a clinical-stage biotechnology company developing gedatolisib, a next-generation inhibitor of the PI3K/AKT/mTOR currently being evaluated in HR+ HER2- patients in the Phase 3 trial VIKTORIA-1. The firm notes early data suggest geda has the potential for a best-in-class PAM pathway inhibitor in patients with PIK3CA mutations and in wild-type patients. Phase 3 VIKTORIA-1 will prospectively segment patients into a PIK3CA WT cohort and a PIK3CA MT cohort, with the WT cohort readout in the second half of 2024 and the MT cohort readout in the first half of 2025. Leerink thinks both readouts have a high likelihood of succeeding based on its review of early datasets and historical expectations for the control arms in this trial.

intratio Posted - 1 month ago

$CELC Celcuity Inc. Our mathematical model lets us believe this equity s value will decrease during the next few days and has really poor long-term fundamentals

intratio Posted - 1 month ago

Celcuity Inc. Our analyst concludes this company s value has a very negative short-term outlook and predicts a gravely bleak future $CELC

intratio Posted - 1 month ago

https://www.intratio.com/stock-forecast/CELC Celcuity Inc. The algorithm is making the inference the stock price of this company will plummet quickly and dramatically and will continue to have a very poor trend over the next months $CELC

Stock_Titan Posted - 1 month ago

$CELC Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call https://www.stocktitan.net/news/CELC/celcuity-inc-schedules-release-of-second-quarter-2024-financial-vnnhfvjmk79w.html

intratio Posted - 1 month ago

https://www.intratio.com/stock-forecast/CELC Celcuity Inc. The artificial intelligence has predicted the value of this stock has a clearly unfavorable short-term setup and predicts a gravely bleak future $CELC

intratio Posted - 1 month ago

$CELC https://www.intratio.com/stock-forecast/CELC Our mathematical model calculated this stock s price action has an extremely bleak prognosis for the near future and has really poor long-term fundamentals

intratio Posted - 1 month ago

https://www.intratio.com/stock-forecast/CELC Celcuity Inc. Our artificial intelligence judges that the stock price of this company will immediately drop precipitously with a very negative long-term outlook $CELC

intratio Posted - 1 month ago

$CELC https://www.intratio.com/stock-forecast/CELC Celcuity Inc. Our trained A.I. reaches the conclusion the price of this stock will depreciate swiftly in the short-term and will suffer a highly negative trend that will persist

NVDAMillionaire Posted - 07/31/24

$CELC Celcuity Inc. (CELC): A Promising Oncology Biotech Poised for Breakthrough http://beyondspx.com/2024/07/30/celcuity-inc-celc-a-promising-oncology-biotech-poised-for-breakthrough/

intratio Posted - 07/31/24

$CELC https://www.intratio.com/stock-forecast/CELC Celcuity Inc. The algorithm foresees the price action of this stock will immediately drop precipitously and foretells a grimly dismal future

intratio Posted - 07/30/24

Celcuity Inc. The model reaches the conclusion that this stock s price action has an extremely bleak prognosis for the near future and has non-existing long-term fundamentals $CELC

DonCorleone77 Posted - 07/22/24

$CELC Celcuity initiated with an Outperform at Leerink Leerink initiated coverage of Celcuity with an Outperform rating and $29 price target. Celcuity is a clinical-stage biotechnology company developing gedatolisib, a next-generation inhibitor of the PI3K/AKT/mTOR currently being evaluated in HR+ HER2- patients in the Phase 3 trial VIKTORIA-1. The firm notes early data suggest geda has the potential for a best-in-class PAM pathway inhibitor in patients with PIK3CA mutations and in wild-type patients. Phase 3 VIKTORIA-1 will prospectively segment patients into a PIK3CA WT cohort and a PIK3CA MT cohort, with the WT cohort readout in the second half of 2024 and the MT cohort readout in the first half of 2025. Leerink thinks both readouts have a high likelihood of succeeding based on its review of early datasets and historical expectations for the control arms in this trial.

intratio Posted - 2 months ago

Celcuity Inc. Our trained A.I. infers this company s stock price will decrease during the next few days and is anticipated to lose heights in the next 90 days $CELC

intratio Posted - 2 months ago

$CELC The mathematical model has detected that the market value of this company has a clearly unfavorable short-term setup and, in the long run, faces severe disadvantages

intratio Posted - 2 months ago

$CELC https://www.intratio.com/stock-forecast/CELC Our advanced model estimates the price action of this stock will fall sharply in the short-term and will have a very negative trend in the upcoming months

Doozio Posted - 2 months ago

$CELC out of da first 🐑 correction of 🧠⏰ is

intratio Posted - 2 months ago

Our engine has forecasted this company s stock price will depreciate swiftly in the short-term and is poised to drop further in the coming weeks $CELC

intratio Posted - 2 months ago

$CELC https://www.intratio.com/stock-forecast/CELC Celcuity Inc. Our mathematical model has detected that the value of this equity has a rather grim outlook for the immediate future and is poised to drop further in the coming weeks

DonCorleone77 Posted - 05/30/24

$CELC Celcuity prices 3.87M shares at $15.50 in underwritten common stock offering Celcuity announced the pricing of an underwritten offering of 3,871,000 shares of its common stock at an offering price of $15.50 per share. All of the securities are to be sold by Celcuity. Investors who have agreed to purchase shares in the offering include BVF Partners, Vivo Capital, Eventide Asset Management, Samlyn Capital, Driehaus Capital Management and Blue Owl Healthcare Opportunities. The offering is expected to close on or about May 31, 2024, subject to satisfaction of customary closing conditions. Gross proceeds to Celcuity from the offering are expected to be $60M, before deducting underwriting discounts and commissions and offering expenses. Celcuity intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, clinical trial expenditures, expansion of business development activities and other general corporate purposes. Clinical trial expenditures may include a Phase 3 clinical trial that Celcuity plans to initiate to evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer. Celcuity expects that its existing cash, cash equivalents and short-term investments and available borrowings under its recently announced amended and restated loan and security agreement, together with the net proceeds from this offering, will be sufficient to fund Celcuity's operating expenses and capital expenditure requirements through at least the second half of 2026. Leerink Partners, TD Cowen and Stifel acted as joint bookrunning managers for the offering.

Stock_Titan Posted - 05/30/24

$CELC Celcuity Announces Pricing of Underwritten Common Stock Offering https://www.stocktitan.net/news/CELC/celcuity-announces-pricing-of-underwritten-common-stock-c7q5yul1fcxv.html

Stock_Titan Posted - 05/30/24

$CELC Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing https://www.stocktitan.net/news/CELC/celcuity-inc-announces-plan-to-initiate-a-phase-3-clinical-trial-for-jar482whvqeu.html

StockInvest_us Posted - 4 months ago

Signal alert: $CELC - Oversold Trend Short (Undervalued) https://stockinvest.us/l/ohy6UU4DZl

DonCorleone77 Posted - 4 months ago

$CELC Celcuity reports Q1 EPS (59c), consensus (71c) "We continued to execute well this quarter. Our VIKTORIA-1 study remains on-track, and we dosed the first patient in our Phase 1b/2 trial in metastatic castration resistant prostate cancer," said Brian Sullivan, Celcuity's Chief Executive Officer and co-founder. "With the addition of a Chief Commercial Officer to our executive team, we began the foundational work needed to prepare for the potential commercial launch of gedatolisib. We look forward to presenting topline data from the PIK3CA wild type patient sub-group later this year."